NeoGenomics has appointed diagnostics and laboratory services veteran John P. “Jack” Kenny to its Board of Directors, adding a senior commercial and operating leader as the company positions itself for what it describes as emerging opportunities in next-generation cancer testing. Kenny fills a seat vacated by Alison Hannah, MD, who is rotating off the board after more than a decade of service.
The appointment comes as NeoGenomics continues to broaden its role across the oncology testing continuum, supporting community-based and hospital-affiliated oncology practices, academic centers, and biopharmaceutical customers with a menu spanning diagnostic, prognostic, and predictive testing. The company said its growth priorities include advanced modalities such as NGS (next-generation sequencing) and MRD (minimal residual disease) testing, areas that have become increasingly important as oncologists seek more precise tools for disease classification, treatment selection, and long-term monitoring.
Kenny brings more than 30 years of experience across diagnostics, medical technology, and lab services, with roles spanning executive leadership, commercial management, and operations. Most recently, he served as President, Chief Executive Officer, and a board director of Meridian Bioscience, a life science company focused on diagnostic products and raw materials used in immunoassay and molecular testing. Meridian, which had traded on Nasdaq under the ticker VIVO, was taken private in January 2023.
Earlier in his career, Kenny held leadership positions at several large healthcare and diagnostics organizations, including serving as Senior Vice President and General Manager of North America at Siemens Healthcare and as Vice President and General Manager of the U.S. region at Becton Dickinson. His background also includes sales leadership roles at Leica Biosystems, Quest Diagnostics, Siemens Medical Solutions, and Abbott Laboratories—experience that NeoGenomics’ board chair highlighted as relevant to building commercial organizations and scaling execution.
NeoGenomics also emphasized Kenny’s broader governance experience. In addition to joining the NeoGenomics board, he serves as a director at OraSure Technologies and holds board roles with DCN Diagnostics and Quantum-Si. The company positioned the addition as strengthening the board’s depth in diagnostics and laboratory services at a time when competition and technological change in oncology testing are accelerating.
For NeoGenomics, which operates CAP-accredited and CLIA-certified laboratory sites across the United States and a CAP-accredited sample-processing laboratory in Cambridge, U.K., the board transition also marks a passing of the baton from a long-serving director. The company credited Hannah with strategic guidance and a sustained commitment to its mission of improving patient care through better cancer diagnostics.
Kenny, for his part, framed NeoGenomics as well-positioned in hematology cancer testing and argued that its footprint in the community setting can help deliver innovation closer to where many patients receive care—an emphasis that aligns with broader industry efforts to extend sophisticated molecular testing beyond major academic centers.
KEY QUOTES:
“We are very excited to welcome Jack to the NeoGenomics Board. His vast experience building winning cultures and leading high performance commercial teams will serve us well as we pursue significant emerging opportunities in the next generation of cancer testing, notably NGS and MRD. I look forward to his insights and guidance.”
“I would also like to thank Dr. Hannah for her strategic guidance over the past decade and her unwavering commitment to NeoGenomics’ mission to save lives by improving patient care. Her contributions have been invaluable.”
Lynn Tetrault, Chair of the Board, NeoGenomics
“I have known NeoGenomics for many years, and I believe their leadership position in hematology cancer testing positions them well to deliver innovation to where it’s needed most – the community setting – improving patient outcomes while creating sustained value for shareholders. I look forward to working alongside my fellow Board members and the passionate NeoGenomics leadership team to help guide the Company through its next phase of growth.”
John P. “Jack” Kenny, Board Director, NeoGenomics
